Which patients should have CYP2C19 genotyping?

Genotyping is most valuable in patients with acute coronary syndrome or planned PCI in whom clopidogrel is being considered, or in those with suspected non-response or recurrent events on therapy. It guides the choice between clopidogrel, prasugrel, and ticagrelor.

What does a poor metaboliser result mean for treatment?

A poor metaboliser (two loss-of-function alleles) will generate little active clopidogrel metabolite and is at high risk for treatment failure. Guidelines recommend switching to prasugrel or ticagrelor, which are not CYP2C19-dependent, or using higher clopidogrel doses with platelet-function monitoring.

Does genotype apply to prasugrel or ticagrelor?

No. Prasugrel and ticagrelor are not significantly metabolised by CYP2C19, so the genotype does not predict their efficacy. They are often preferred in intermediate or poor metabolisers precisely because their activity is independent of this enzyme.

Can the genotype result change over time or with other medications?

Genotype is fixed from birth and does not change. However, strong CYP2C19 inhibitors — proton-pump inhibitors like omeprazole, or drugs such as fluconazole — can phenoconvert a normal metaboliser to a functionally poor metaboliser, so drug interactions must be considered alongside genotype.

Is fasting or special preparation required for this test?

No. CYP2C19 genotyping uses DNA from whole blood, which is unaffected by diet, time of day, or current medications. Standard venepuncture into an EDTA tube is all that is required.

How long does CYP2C19 genotyping take?

Turnaround is typically 5–10 business days from specimen receipt at Boston Heart Diagnostics. Expedited processing may be available for urgent clinical decisions in acute coronary syndrome; confirm with the laboratory.

Should all patients on clopidogrel be genotyped?

Not necessarily. Some high-volume centres use ticagrelor or prasugrel as default therapy in ACS and PCI, making genotyping less critical. Genotyping is most useful when clopidogrel is the intended or only feasible P2Y12 inhibitor, or in settings with institutional genotype-guided protocols.

Are there consent or privacy considerations for genetic testing?

Yes. Genetic results are permanent and may have implications beyond the immediate clinical question. Practitioners should document informed consent, discuss privacy protections under HIPAA or equivalent regulations, and clarify that this is a pharmacogenomic tool, not a diagnostic test for inherited disease.

BML-GEN-014genetic testingUSA

Clopidogrel Response (CYP2C19) Genotype Add-On

The CYP2C19 Genotype Add-On identifies inherited variants that determine clopidogrel bioactivation capacity. Loss-of-function alleles (*2, *3) predict intermediate or poor metaboliser status, attenuated platelet inhibition, and higher post-PCI thrombotic risk, guiding practitioners to consider prasugrel, ticagrelor, or adjusted clopidogrel dosing in acute coronary syndrome and PCI populations.

Biomarkers

Blood (whole blood)

Sample

5–10 business days

Turnaround

Fasting

What is the CYP2C19 Genotype test?

The CYP2C19 Genotype Add-On identifies inherited variants in the gene encoding cytochrome P450 2C19, the enzyme responsible for bioactivating clopidogrel to its active antiplatelet metabolite. Because loss-of-function alleles impair activation and predict diminished platelet inhibition and higher post-procedural thrombotic event rates, genotyping allows practitioners to stratify cardiovascular risk and tailor P2Y12 inhibitor selection before or shortly after percutaneous coronary intervention. This test is an add-on — typically ordered alongside or as part of a cardiovascular risk or lipid panel — and its clinical value is greatest in acute coronary syndrome or elective PCI populations where antiplatelet therapy will be initiated or adjusted. Genotype-guided prescribing is supported by pharmacogenomics guidelines and increasingly by payer policies, though real-world adoption varies and some centres have moved to universal use of ticagrelor or prasugrel in high-risk patients, rendering genotyping less critical in those pathways.

What does the CYP2C19 Genotype test measure?

CYP2C19(Cytochrome P450 2C19 Genotype)

Range: Not applicable; results report star-allele diplotype and predicted metaboliser phenotype (ultrarapid, rapid, normal, intermediate, poor).Optimal: The 'optimal' genotype in the context of clopidogrel therapy is normal (extensive) or rapid/ultrarapid metaboliser status, predicting adequate prodrug activation; intermediate and poor metaboliser phenotypes confer increased risk of treatment failure.Genotype classification

CYP2C19 is a hepatic cytochrome P450 isoenzyme encoded on chromosome 10q23.33 that metabolises roughly 10% of clinically used drugs, including the prodrug clopidogrel. Clopidogrel requires two-step bioactivation, with CYP2C19-mediated oxidation a rate-limiting step; the active thiol metabolite then irreversibly inhibits the platelet P2Y12 ADP receptor. Loss-of-function alleles (*2, *3, and others) reduce enzyme activity, while gain-of-function alleles (*17) increase it. An individual's diplotype — the pair of inherited alleles — determines their metaboliser phenotype, which in turn governs the magnitude and reliability of platelet inhibition achieved on standard clopidogrel doses.

Carriers of one or two loss-of-function alleles generate less active metabolite, experience attenuated platelet inhibition, and face higher rates of major adverse cardiovascular events after percutaneous coronary intervention. Guidelines from pharmacogenomics consortia recommend genotype-guided selection of P2Y12 inhibitor therapy: patients identified as intermediate or poor metabolisers may benefit from an alternative agent (prasugrel or ticagrelor) or from higher clopidogrel doses, though prasugrel and ticagrelor are not themselves CYP2C19-dependent and are often preferred in high-risk settings regardless of genotype.

Why is the CYP2C19 Genotype test ordered?

Patients with acute coronary syndrome or planned percutaneous coronary intervention in whom clopidogrel is being considered as the P2Y12 inhibitor
Evaluation of suspected clopidogrel non-response or recurrent ischaemic events on therapy, where a genetic explanation may guide switching to prasugrel or ticagrelor
Preemptive pharmacogenomic screening in patients with established coronary artery disease who may require antiplatelet therapy in future, allowing genotype to inform the choice at the time of an event
Settings where prasugrel or ticagrelor are contraindicated or unavailable and clinicians wish to identify patients who will require higher clopidogrel doses or alternative strategies
Patients enrolled in clinical pathways or institutional protocols that incorporate routine CYP2C19 genotyping into post-PCI care
Investigation of drug–gene interactions in complex polypharmacy, where CYP2C19 status may also affect proton-pump inhibitor metabolism and other substrates

Sample collection and turnaround

Sample type

Blood (whole blood)

Fasting required

Collection method

Venipuncture at patient service centre

Turnaround

5–10 business days

Collection notes

Phlebotomy at a centre that routes to Boston Heart Diagnostics; EDTA whole blood is preferred. DNA is stable in whole blood for extended periods when stored appropriately. No special preparation or fasting is required; genotype is constitutional and unaffected by diet, time of day, or concurrent medications.

Specimen requirements

EDTA whole blood, typically 2–5 mL; confirm minimum volume and any kit requirements with the performing laboratory. Avoid haemolysed specimens if DNA yield is a concern, though modern extraction is generally robust.

What can affect CYP2C19 Genotype results?

variableGermline genetic result — preanalytical stability

Genotype is fixed at conception and does not change, so specimen age, haemolysis, or metabolic state do not alter the result; however, DNA extraction quality and assay coverage of rare or novel alleles can vary between platforms.

variablePopulation ancestry and rare alleles

Most panels detect common loss-of-function (*2, *3) and gain-of-function (*17) alleles; rare or population-specific variants may be missed, leading to misclassification. Laboratories typically report detected alleles and assign *1 (wild type) by default to undetected positions.

variableSomatic mosaicism and chimerism

Germline genotyping assumes constitutional DNA; bone-marrow transplant recipients or individuals with high-level somatic mosaicism may yield results that do not reflect liver enzyme phenotype.

variableConcomitant CYP2C19 inhibitors

Genotype predicts intrinsic enzyme capacity, but strong inhibitors (omeprazole, esomeprazole, fluconazole, fluvoxamine) can phenoconvert a normal metaboliser to an intermediate or poor phenotype; the genetic result does not capture acquired inhibition.

variableAssay platform and allele nomenclature

Different laboratories may use distinct genotyping technologies (array, targeted sequencing, qPCR) and may report star-allele diplotypes or phenotype predictions; ensure serial results come from the same platform for consistency.

What do CYP2C19 Genotype results mean?

Elevated

Not applicable — genotype results report allele combinations and predicted phenotype (ultrarapid, rapid, normal, intermediate, poor metaboliser), not quantitative elevation.

Normal

Normal (extensive) metaboliser, rapid metaboliser, or ultrarapid metaboliser phenotypes predict adequate or enhanced clopidogrel bioactivation and standard antiplatelet response. Standard dosing is appropriate, though clinical factors (diabetes, renal impairment, concomitant inhibitors) may still influence response and should be integrated into the overall management plan.

Reduced

Intermediate metaboliser (one loss-of-function allele) or poor metaboliser (two loss-of-function alleles, e.g. *2/*2, *2/*3) phenotypes predict reduced clopidogrel bioactivation, attenuated platelet inhibition, and increased risk of stent thrombosis and major adverse cardiovascular events. Guidelines recommend considering an alternative P2Y12 inhibitor (prasugrel, ticagrelor) or, if clopidogrel is preferred, higher loading and maintenance doses with platelet-function testing to confirm response.

Note: CYP2C19 genotype is one determinant of clopidogrel response; non-genetic factors (drug interactions, adherence, platelet reactivity, clinical acuity) also matter. Genotype does not apply to prasugrel or ticagrelor, which are not CYP2C19-dependent. Results are germline and do not change, so once obtained the genotype informs all future prescribing decisions; however, clinical guidelines and payer policies evolve, and some high-volume centres have adopted ticagrelor or prasugrel as default therapy, reducing reliance on genotyping. Informed consent and discussion of the implications — including potential insurance and data-privacy considerations — are essential before ordering any genetic test.

Frequently asked questions

CYP2C19 is the hepatic enzyme that activates clopidogrel from a prodrug to its active antiplatelet form. Genetic variants that reduce enzyme activity lead to lower active metabolite levels, weaker platelet inhibition, and higher rates of stent thrombosis and cardiovascular events after PCI.

How to access the CYP2C19 Genotype test

The CYP2C19 Genotype reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: October 7, 2026

Last reviewed: October 7, 2026

References:

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C19 and clopidogrel therapy (2022)
Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. (2013)
Mega JL, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. (2009)
Levine GN, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease (2016)
Sibbing D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. (2019)

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.

Related tests

cardiovascular

ApoB

The ApoB test measures apolipoprotein B, the structural protein present on all atherogenic lipoproteins (VLDL, IDL, LDL, Lp(a)), providing a direct particle count that is superior to LDL cholesterol for cardiovascular risk stratification, particularly in metabolic syndrome, diabetes, and hypertriglyceridaemia, and guides lipid-lowering therapy intensity and adequacy.

BML-CAR-049View reference →